Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $255,750.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the transaction, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Thursday, October 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total value of $156,827.06.
• On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $141,494.34.

Xeris Biopharma Stock Up 1.1%

Shares of XERS stock traded up $0.11 during trading hours on Wednesday, reaching $10.46. 3,142,009 shares of the company’s stock were exchanged, compared to its average volume of 2,030,196. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $11.41. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The stock has a market cap of $1.91 billion, a PE ratio of -95.09 and a beta of 0.61. The stock’s fifty day moving average price is $9.37 and its two-hundred day moving average price is $7.54.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays lifted their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Finally, Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.20.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Xeris Biopharma during the 2nd quarter valued at about $115,042,000. Wellington Management Group LLP boosted its stake in shares of Xeris Biopharma by 8.9% in the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after buying an additional 193,749 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Xeris Biopharma in the second quarter worth about $15,941,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Xeris Biopharma in the second quarter worth about $14,316,000. Finally, Algert Global LLC grew its holdings in Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock worth $13,804,000 after acquiring an additional 585,984 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.